journal
Journals Journal of the National Compre...

Journal of the National Comprehensive Cancer Network : JNCCN

https://read.qxmd.com/read/38776960/decline-in-smartphone-assessed-physical-activity-level-is-associated-with-clinical-outcomes-in-phase-i-ii-clinical-cancer-trials
#1
JOURNAL ARTICLE
Calvin G Brouwer, Joeri A J Douma, Evelien J M Kuip, Sonja Zweegman, Niels W C J van de Donk, Maria T E Hopman, Myra E van Linde, Henk M W Verheul, Laurien M Buffart
BACKGROUND: A decline in physical function may be an early predictor for complications of cancer treatment. This study examined whether repeated objective smartphone measurements of physical activity and exercise capacity in patients with cancer are feasible during early-phase clinical trials (EPCTs) and whether a decline in physical function is associated with clinical outcomes. METHODS: Physical activity (steps/day) and exercise capacity (6-minute walk test [6MWT]) were measured with a smartphone before EPCT start (T0) and after 4 weeks (T1) and 8 weeks (T2)...
May 22, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38749478/enhancing-readability-of-online-patient-facing-content-the-role-of-ai-chatbots-in-improving-cancer-information-accessibility
#2
JOURNAL ARTICLE
Andres A Abreu, Gilbert Z Murimwa, Emile Farah, James W Stewart, Lucia Zhang, Jonathan Rodriguez, John Sweetenham, Herbert J Zeh, Sam C Wang, Patricio M Polanco
BACKGROUND: Internet-based health education is increasingly vital in patient care. However, the readability of online information often exceeds the average reading level of the US population, limiting accessibility and comprehension. This study investigates the use of chatbot artificial intelligence to improve the readability of cancer-related patient-facing content. METHODS: We used ChatGPT 4.0 to rewrite content about breast, colon, lung, prostate, and pancreas cancer across 34 websites associated with NCCN Member Institutions...
May 15, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38744314/efficacy-and-toxicity-analysis-of-mfolfirinox-in-high-grade-gastroenteropancreatic-neuroendocrine-neoplasms
#3
JOURNAL ARTICLE
Michele Borghesani, Anna Reni, Eleonora Lauricella, Alice Rossi, Viola Moscarda, Elena Trevisani, Irene Torresan, Taymeyah Al-Toubah, Elisabetta Filoni, Claudio Luchini, Riccardo De Robertis, Luca Landoni, Aldo Scarpa, Camillo Porta, Michele Milella, Jonathan Strosberg, Mauro Cives, Sara Cingarlini
BACKGROUND: High-grade neuroendocrine neoplasms (NENs) comprise both well-differentiated grade 3 neuroendocrine tumors (G3 NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) nearly always include poorly differentiated NEC as the neuroendocrine component. The efficacy and safety of frontline mFOLFIRINOX chemotherapy has never been investigated in patients with high-grade NENs. PATIENTS AND METHODS: We conducted a multi-institutional retrospective analysis of patients with advanced high-grade NEN of the gastroenteropancreatic tract or of unknown origin seen between February 2016 and April 2023 who received treatment with frontline mFOLFIRINOX...
May 14, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38744306/outcomes-in-nonmetastatic-hormone-receptor-positive-her2-negative-pure-mucinous-breast-cancer-a-multicenter-cohort-study
#4
JOURNAL ARTICLE
Ryan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, Seri Park, Jabed Iqbal, Yeon Hee Park, Jeong Eon Lee, Jong Han Yu, Ching-Hung Lin, Yen-Shen Lu, Makiko Ono, Takayuki Ueno, Yoichi Naito, Tatsuya Onishi, Geok-Hoon Lim, Su-Ming Tan, Han-Byoel Lee, Jiwon Koh, Wonshik Han, Seock-Ah Im, Veronique Kiak Mien Tan, Nitar Phyu, Fuh-Yong Wong, Puay Hoon Tan, Yoon-Sim Yap
BACKGROUND: Although considered a favorable subtype, pure mucinous breast cancer (PMBC) can recur, and evidence for adjuvant therapy is limited. We aimed to compare outcomes of nonmetastatic PMBC with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) to address these uncertainties. METHODS: Individual patient-level data from 6 centers on stage I-III hormone receptor-positive and HER2-negative PMBC, IDC, and ILC were used to analyze recurrence-free interval (RFI), recurrence-free survival (RFS), and overall survival (OS), and to identify prognostic factors for PMBC...
May 14, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38729204/implementation-of-universal-hepatitis-c-virus-screening-in-a-tertiary-cancer-center
#5
JOURNAL ARTICLE
Harrys A Torres, Khalis Mustafayev, Ruston P Juneau, Jessica P Hwang, Lan Sun Wang, Georgios Angelidakis, Ernest Hawk, Bruno P Granwehr, Eduardo Yepez Guevara, Anita K Ying
BACKGROUND: The prevalence of chronic hepatitis C virus (HCV) infection in the United States is ≤1%. Universal HCV screening is recommended nationwide. Here we describe our experience implementing universal HCV screening at a cancer center. METHODS: In October 2016, universal HCV screening with HCV antibody (anti-HCV) was initiated for all new outpatients. Universal screening was promoted through widespread provider education, orders in the Epic electronic health records (EHRs), SmartSets, and automated EHR reminders...
May 10, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38688309/failure-to-undergo-resection-following-neoadjuvant-therapy-for-resectable-pancreatic-cancer-a-secondary-analysis-of-swog-s1505
#6
JOURNAL ARTICLE
Jordan M Cloyd, Sarah Colby, Katherine A Guthrie, Andy M Lowy, E Gabrielle Chiorean, Phillip Philip, Davendra Sohal, Syed Ahmad
BACKGROUND: Neoadjuvant therapy (NT) is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), and yet reasons for not undergoing subsequent pancreatectomy are poorly understood. Given the importance of completing multimodality therapy, we investigated factors associated with failure to undergo surgical resection following NT for PDAC. METHODS: SWOG S1505 was a multicenter phase II randomized trial of preoperative mFOLFIRINOX or gemcitabine/nab-paclitaxel prior to planned pancreatectomy for patients with potentially resectable PDAC...
April 29, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38688308/real-world-use-of-hypofractionated-radiotherapy-for-primary-cns-tumors-in-the-elderly-and-implications-on-medicare-spending
#7
JOURNAL ARTICLE
Kathryn R Tringale, Andrew Lin, Alexandra M Miller, Atif Khan, Linda Chen, Melissa Zinovoy, Yoshiya Yamada, Yao Yu, Luke R G Pike, Brandon S Imber
BACKGROUND: For elderly patients with high-grade gliomas, 3-week hypofractionated radiotherapy (HFRT) is noninferior to standard long-course radiotherapy (LCRT). We analyzed real-world utilization of HFRT with and without systemic therapy in Medicare beneficiaries treated with RT for primary central nervous system (CNS) tumors using Centers for Medicare & Medicaid Services data. METHODS: Radiation modality, year, age (65-74, 75-84, or ≥85 years), and site of care (freestanding vs hospital-affiliated) were evaluated...
April 29, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38663443/loneliness-and-mortality-risk-among-cancer-survivors-in-the-united-states-a-retrospective-longitudinal-study
#8
JOURNAL ARTICLE
Jingxuan Zhao, Jennifer B Reese, Xuesong Han, K Robin Yabroff
BACKGROUND: Loneliness, a subjective feeling of being isolated, is a prevalent concern for elderly people and more so among cancer survivors because a cancer diagnosis and its subsequent treatment may result in long-term adverse health effects. This study aimed to examine the association of loneliness and mortality risk among cancer survivors in the United States. METHODS: We identified a longitudinal cohort of cancer survivors aged ≥50 years from the nationally representative panel surveys of the 2008-2018 Health and Retirement Study...
April 25, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38670152/geographic-accessibility-and-completion-of-initial-low-dose-ct-based-lung-cancer-screening-in-an-urban-safety-net-population
#9
JOURNAL ARTICLE
Sofia Yi, Rutu A Rathod, Vijaya Subbu Natchimuthu, Sheena Bhalla, Jessica L Lee, Travis Browning, Joyce O Adesina, Minh Do, David Balis, Juana Gamarra de Wiliams, Ellen Kitchell, Noel O Santini, David H Johnson, Heidi A Hamann, Simon J Craddock Lee, Amy E Hughes, David E Gerber
BACKGROUND: Recent modifications to low-dose CT (LDCT)-based lung cancer screening guidelines increase the number of eligible individuals, particularly among racial and ethnic minorities. Because these populations disproportionately live in metropolitan areas, we analyzed the association between travel time and initial LDCT completion within an integrated, urban safety-net health care system. METHODS: Using Esri's StreetMap Premium, OpenStreetMap, and the r5r package in R, we determined projected private vehicle and public transportation travel times between patient residence and the screening facility for LDCT ordered in March 2017 through December 2022 at Parkland Memorial Hospital in Dallas, Texas...
April 23, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38653321/revisiting-the-association-of-ecog-performance-status-with-clinical-outcomes-in-diverse-patients-with-cancer
#10
JOURNAL ARTICLE
Deepika Kumar, Elad Neeman, Shiyun Zhu, Hongxin Sun, Dinesh Kotak, Raymond Liu
BACKGROUND: The ECOG performance status (PS) scale was developed to support national clinical trials, but the degree to which ECOG PS predicts clinical outcomes in patient subgroups outside of clinical trials is relatively unknown. This study examined associations between ECOG PS and adverse outcomes in a diverse community oncology population. PATIENTS AND METHODS: In this retrospective cohort study, demographic and clinical characteristics, including the most recent ECOG PS between January 1, 2017, and December 31, 2019, were examined for patients receiving cancer treatment within Kaiser Permanente Northern California (KPNC)...
April 23, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38648855/breakthrough-therapy-cancer-drugs-and-indications-with-fda-approval-development-time-innovation-trials-clinical-benefit-epidemiology-and-price
#11
JOURNAL ARTICLE
Daniel Tobias Michaeli, Thomas Michaeli
BACKGROUND: The breakthrough therapy designation (BTD) facilitates the development of drugs with a large preliminary benefit in treating serious or life-threatening diseases. This study analyzes the FDA approval, trials, benefits, unmet needs, and pricing of breakthrough and nonbreakthrough therapy cancer drugs and indications. PATIENTS AND METHODS: We analyzed 355 cancer indications with FDA approval (2012-2022). Breakthrough and nonbreakthrough indications were compared regarding their FDA approval, innovativeness, clinical trials, epidemiology, and price...
April 22, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38648848/life-years-gained-from-the-fda-accelerated-approval-program-in-oncology-a-portfolio-model
#12
JOURNAL ARTICLE
Ágnes Benedict, Gábor Szabó, Kinga Marczell, Bridget Doherty, Silas Martin
BACKGROUND: Although the FDA Accelerated Approval Program (AAP) has come under scrutiny, the population-level health benefit of the program has not been quantified. Therefore, the objective of this study was to estimate the number of life years gained among patients with cancer that can be attributable to the therapies receiving FDA accelerated approvals in oncology between 2006 and 2022 in the United States. METHODS: The data sources used were FDA listings, FDA approval letters and labels, published clinical trial data and other publications including relative effectiveness estimates, and the Ipsos Oncology Uptake Tool for product uptake...
April 22, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38648846/health-care-lobbying-and-oncology
#13
JOURNAL ARTICLE
Nirmal Choradia, Aaron Mitchell, Ryan Nipp
BACKGROUND: The health care industry spends more on lobbying than any other industry, with more than $700 million spent in 2022. However, health care lobbying related to cancer has not been characterized. In this study, we sought to describe overall health sector lobbying spending and oncology-related lobbying spending across patient and clinician organizations. METHODS: We obtained lobbying data from OpenSecrets.org and the Federal Election Commission. Overall health sector lobbying spending was categorized by OpenSecrets into 4 groups: pharmaceuticals/health products, health services/health maintenance organizations (HMOs), hospitals/nursing homes, and health professionals...
April 19, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38640946/barriers-and-facilitators-impacting-lung-cancer-screening-uptake-among-black-veterans-a-qualitative-study
#14
JOURNAL ARTICLE
Neelima Navuluri, Tiera Lanford, Abigail Shapiro, Govind Krishnan, Angela B Johnson, Isaretta L Riley, Leah L Zullig, Christopher E Cox, Scott Shofer
BACKGROUND: Racial disparities in lung cancer screening (LCS) are well established. Black Veterans are among those at the highest risk for developing lung cancer but are less likely to complete LCS. We sought to identify barriers and facilitators to LCS uptake among Black Veterans. PATIENTS AND METHODS: A qualitative study using semistructured interviews was conducted with 32 Black Veterans to assess for barriers, facilitators, and contextual factors for LCS and strategies to improve screening...
April 18, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38631387/racial-differences-in-germline-genetic-testing-completion-among-males-with-pancreatic-breast-or-metastatic-prostate-cancers
#15
JOURNAL ARTICLE
Jeffrey W Shevach, Danielle Candelieri-Surette, Julie A Lynch, Rebecca A Hubbard, Patrick R Alba, Karen Glanz, Ravi B Parikh, Kara N Maxwell
BACKGROUND: Germline genetic testing is a vital component of guideline-recommended cancer care for males with pancreatic, breast, or metastatic prostate cancers. We sought to determine whether there were racial disparities in germline genetic testing completion in this population. PATIENTS AND METHODS: This retrospective cohort study included non-Hispanic White and Black males with incident pancreatic, breast, or metastatic prostate cancers between January 1, 2019, and September 30, 2021...
April 17, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38503050/key-performance-indicators-and-metrics-for-the-implementation-of-an-oral-chemotherapy-adherence-program
#16
JOURNAL ARTICLE
Benyam Muluneh, James B Collins, Brian Lam, Emily Mackler, Jennifer Elston Lafata
BACKGROUND: Oral anticancer agents (OAAs) transformed cancer care for patients, extending survival and delaying progression in certain cases. There are multiple pharmacy-driven models to improve patient knowledge and adherence to OAAs. However, a lack of measurable key performance indicators (KPIs) has limited the adoption, implementation, and maintenance of these models. The objective of this study was to identify a set of KPIs, their metrics, and the target values that indicated improved patient care through an OAA adherence program...
March 19, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38503041/gastroesophageal-adenocarcinomas-with-defective-mismatch-repair-current-knowledge-and-clinical-management
#17
REVIEW
Matthew R Strickland, Eric M Lander, Michael K Gibson, David H Ilson, Jaffer A Ajani, Samuel J Klempner
Esophageal, gastroesophageal junction, and gastric adenocarcinomas, referred to collectively as gastroesophageal adenocarcinomas (GEAs), are a major cause of global cancer-related mortality. Our increasing molecular understanding has led to the addition of biomarker-directed approaches to defined subgroups and has improved survival in selected patients, such as those with HER2 and Claudin18.2 overexpression. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, including GEA, but biomarkers beyond PD-L1 expression are lacking...
March 19, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38498975/long-term-outcomes-of-dmmr-msi-h-rectal-cancer-treated-with-anti-pd-1-based-immunotherapy-as-curative-intent-treatment
#18
JOURNAL ARTICLE
Jie-Hai Yu, Le-En Liao, Bin-Yi Xiao, Xuan Zhang, Ai-Wen Wu, Yong Cheng, Jing-Hua Tang, Wu Jiang, Ling-Heng Kong, Kai Han, Wei-Jian Mei, Zhi-Gang Hong, Wan-Jun Yang, Dan-Dan Li, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, Pei-Rong Ding
BACKGROUND: Neoadjuvant anti-PD-1 therapy has shown encouraging efficacy in patients with deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer (LARC), which suggests its potential as a curative-intent therapy and a promising treatment option for organ preservation. We aimed to investigate the long-term outcomes of patients with dMMR/MSI-H LARC who experienced clinical complete response (cCR) after anti-PD-1 therapy. METHODS: We retrospectively analyzed patients with dMMR/MSI-H LARC who achieved cCR and received nonoperative management following neoadjuvant anti-PD-1-based treatment from 4 Chinese medical centers...
March 18, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38498974/treatment-patterns-and-survival-outcomes-in-patients-with-breast-cancer-on-medicaid-pre-and-post-expansion
#19
JOURNAL ARTICLE
Siran M Koroukian, Weichuan Dong, Jeffrey M Albert, Uriel Kim, Kirsten Eom, Johnie Rose, Cynthia Owusu, Kristine M Zanotti, Gregory Cooper, Jennifer Tsui
BACKGROUND: The objective of this study was to evaluate the impact of Medicaid expansion on breast cancer treatment and survival among Medicaid-insured women in Ohio, accounting for the timing of enrollment in Medicaid relative to their cancer diagnosis and post-expansion heterogeneous Medicaid eligibility criteria, thus addressing important limitations in previous studies. METHODS: Using 2011-2017 Ohio Cancer Incidence Surveillance System data linked with Medicaid claims data, we identified women aged 18 to 64 years diagnosed with local-stage or regional-stage breast cancer (n=876 and n=1,957 pre-expansion and post-expansion, respectively)...
March 18, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38489927/effect-of-patient-navigation-on-completion-of-lung-cancer-screening-in-vulnerable-populations
#20
JOURNAL ARTICLE
Sheena Bhalla, Vijaya Natchimuthu, Jessica L Lee, Urooj Wahid, Hong Zhu, Noel O Santini, Travis Browning, Heidi A Hamann, David H Johnson, Hsienchang Chiu, Simon J Craddock Lee, David E Gerber
BACKGROUND: Although low-dose, CT-based lung cancer screening (LCS) can decrease lung cancer mortality in high-risk individuals, the process may be complex and pose challenges to patients, particularly those from minority underinsured and uninsured populations. We conducted a randomized controlled trial of telephone-based navigation for LCS within an integrated, urban, safety-net health care system. PATIENTS AND METHODS: Patients eligible for LCS were randomized (1:1) to usual care with or without navigation at Parkland Health in Dallas, Texas...
March 15, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.